FOLFOXIRI therapy with bevacizumab in metastatic colorectal cancer patient: Systematic review

被引：0
|
作者：
Subroto, Dion Ravinder Theodeus [1 ]
Sutanto, Mario [1 ]
Law, Natasha Karlina [1 ]
Lee, Jonathan Vincent [1 ]
Kumar, Chandni [1 ]
Siregar, Axel Sebastian [1 ]
Sihombing, Andreas [1 ]
Ang, Xavier Manuel [1 ]
Kurniawan, Andree [2 ]
机构：
[1] Pelita Harapan Univ, Fac Med, Tangerang, Indonesia
[2] Pelita Harapan Univ, Fac Med, Dept Internal Med, Tangerang, Indonesia
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.398
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P47-1
引用
收藏
页码：S1459 / S1459
页数：1
相关论文
共 50 条
  • [1] Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
    Loupakis, Fotios
    Cremolini, Chiara
    Masi, Gianluca
    Lonardi, Sara
    Zagonel, Vittorina
    Salvatore, Lisa
    Cortesi, Enrico
    Tomasello, Gianluca
    Ronzoni, Monica
    Spadi, Rosella
    Zaniboni, Alberto
    Tonini, Giuseppe
    Buonadonna, Angela
    Amoroso, Domenico
    Chiara, Silvana
    Carlomagno, Chiara
    Boni, Corrado
    Allegrini, Giacomo
    Boni, Luca
    Falcone, Alfredo
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (17): : 1609 - 1618
  • [2] FOLFOXIRI and bevacizumab in metastatic colorectal cancer
    Rahman, Ahmadur
    [J]. LANCET ONCOLOGY, 2014, 15 (13): : E590 - E590
  • [3] FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
    Haines, Ian E.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (03): : 290 - 291
  • [4] FOLFOXIRI plus Bevacizumab in metastatic colorectal Cancer
    不详
    [J]. ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2020, 58 (07): : 630 - 630
  • [5] FOLFOXIRI Plus Bevacizumab as Conversion Therapy for Patients With Initially Unresectable Metastatic Colorectal Cancer A Systematic Review and Pooled Analysis
    Tomasello, Gianluca
    Petrelli, Fausto
    Ghidini, Michele
    Russo, Alessandro
    Passalacqua, Rodolfo
    Barni, Sandro
    [J]. JAMA ONCOLOGY, 2017, 3 (07)
  • [6] Intensified First Line Therapy of the metastatic colorectal Cancer with FOLFOXIRI plus Bevacizumab
    Ruessel, J.
    [J]. ONKOLOGE, 2015, 21 (04): : 334 - 335
  • [7] Management of FOLFOXIRI and Bevacizumab therapy for colorectal cancer patients
    Kagawa, Yoshinori
    Naito, Atsushi
    Kawai, Kenji
    Mori, Ryota
    Sakamoto, Takuya
    Murakami, Kohei
    Katsura, Yoshiteru
    Omura, Yoshiaki
    Masuzawa, Toru
    Takeno, Atsushi
    Takeda, Yutaka
    Kato, Takeshi
    Murata, Kohei
    [J]. CANCER SCIENCE, 2018, 109 : 673 - 673
  • [8] Should FOLFOXIRI Plus Bevacizumab Be the Standard First-Line Therapy in Metastatic Colorectal Cancer?
    Nipp, Ryan D.
    Ryan, David P.
    [J]. ONCOLOGIST, 2015, 20 (03): : 236 - 238
  • [9] FOLFOXIRI Regimen for Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis
    Leal, Frederico
    Ferreira, Fernanda Proa
    Sasse, Andre Deeke
    [J]. CLINICAL COLORECTAL CANCER, 2017, 16 (04) : 405 - +
  • [10] Individual Patient Data Meta-Analysis of FOLFOXIRI Plus Bevacizumab Versus Doublets Plus Bevacizumab as Initial Therapy of Unresectable Metastatic Colorectal Cancer
    Cremolini, Chiara
    Antoniotti, Carlotta
    Stein, Alexander
    Bendell, Johanna
    Gruenberger, Thomas
    Rossini, Daniele
    Masi, Gianluca
    Ongaro, Elena
    Hurwitz, Herbert
    Falcone, Alfredo
    Schmoll, Hans-Joachim
    Di Maio, Massimo
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (28) : 3314 - 3324
12345